Alexander Hergovich obtained his Diploma in biology/genetics from the University of Vienna, Austria. He was then awarded a Ph.D. fellowship by the Friedrich Miescher Institute (FMI) in Basel, Switzerland. During his fellowship, he was very interested in studying and understanding mechanisms that counteract tumour growth. After completing his Ph.D. degree in defining novel functions of the Von Hippel-Lindau tumour suppressor protein, Dr. Hergovich secured funding from the Roche Research Foundation and the Swiss Cancer League, which allowed him to study components of the mammalian Hippo tumour suppressor pathway in the laboratory of Dr. Hemmings at the FMI. In 2008, Dr. Hergovich was awarded the Max Burger prize by the FMI for outstanding research achievements as a postdoctoral research fellow. In 2009, he was awarded a prestigious Wellcome Trust Research Career Development fellowship to establish his research group at the UCL Cancer Institute in London, UK. Funded by the Wellcome Trust, the Association for International Cancer Research (AICR), and the Biotechnology and Biological Sciences Research Council (BBSRC), Dr. Hergovich’s laboratory is currently combining biochemistry, molecular biology, and cell biology approaches in order to decipher, at the molecular level, the key tumour suppressing steps of the mammalian Hippo signaling network. Of particular interest to him is to understand how centrosome biology, cell cycle progression, cell proliferation, and apoptosis are controlled by the complex Hippo machinery. Currently ongoing is the dissection of the biological importance of protein-protein interactions and kinase activities in mammalian Hippo signaling by the use of a series of mutant variants of MST/hMOB1/NDR/LATS proteins.
Biography Updated on 30 July 2012